Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Next Science Limited
  6. News
  7. Summary
    NXS   AU0000041329

NEXT SCIENCE LIMITED

(NXS)
  Report
Delayed Australian Stock Exchange  -  02:10 2022-09-27 am EDT
0.7850 AUD   -2.48%
08/26Next Science Secures License for Wound Cleaning Product in Canada
MT
08/25Next Science Limited Announces Health Canada Given Licensing Approval for XPERIENCE
CI
08/24Transcript : Next Science Limited, H1 2022 Earnings Call, Aug 25, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Next Science Limited Signed Multi-Year Distribution Agreement with Oraderm Pharmaceuticals

05/18/2022 | 09:40pm EDT

Next Science Limited announced that it has signed a multi-year distribution agreement for Australia and New Zealand with Oraderm Pharmaceuticals, a medical sales joint venture between Douglas Pharmaceuticals and Arrotex Pharmaceuticals, for the sale of Next Science's antimicrobial wound gel, BlastX. The new distribution agreement grants Oraderm exclusive rights across Australia and New Zealand for the sale and marketing of a dual Next Science /Oraderm labelled version of BlastX. Revenues arising from the agreement are based on an agreed unit price and a minimum quantity per order.

Next Science expects the revenues received from sales of BlastX to Oraderm to become material. The agreement term is 5 years and automatically extends for an additional period of 3 years subject to each party's termination rights. BlastX is an antimicrobial wound gel based on Next Science's patented, non-toxic, biofilm- disrupting Xbio technology.

BlastX deconstructs the bacterial biofilm, the gel envelops and eliminates the bacteria and then defends from recolonisation while maintaining a moist wound environment conducive to healing. The product is ideal for the treatment of non- healing wounds such as foot and leg ulcers and bed sores as well as preventing infections in acute wounds from trauma and surgical incision sites. BlastX can be used in hospital, pre- hospital, aged care and other clinical environments as well as in home care.

BlastX was cleared by the Australian Therapeutic Goods Administration in May 2021 allowing sales in Australia and New Zealand. The product has also received FDA 510(k) clearance and CE marking and is approved for sale in Canada. Oraderm's initial focus in Australia will be hospitals, nursing homes, dermatologists and over- the-counter pharmacy sales using Oraderm's own sales force.

In New Zealand, Oraderm will focus on wound care in hospitals and other clinical settings accommodating varied distribution solutions through Douglas Pharmaceuticals' sales team. Next Science is scheduled to deliver training to the Oraderm and Douglas Pharmaceuticals' sales force in late June with commercial sales in Australia and New Zealand expected to commence during second half of 2022. Chronic wounds continue to be a major health issue for patients across the global community.

They are often very difficult to treat, increase pain and suffering, cause a decline in quality of life, increase mortality and add considerable costs to healthcare systems and individuals. It is estimated that more than 400,000 people in Australia suffer from a chronic wound at any time.


© S&P Capital IQ 2022
All news about NEXT SCIENCE LIMITED
08/26Next Science Secures License for Wound Cleaning Product in Canada
MT
08/25Next Science Limited Announces Health Canada Given Licensing Approval for XPERIENCE
CI
08/24Transcript : Next Science Limited, H1 2022 Earnings Call, Aug 25, 2022
CI
08/24Next Science Limited Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/25Next Science : Investor Presentation - Q2 2022
PU
05/27Next Science CEO to Resign Before June 30, 2023
MT
05/27Transcript : Next Science Limited - Shareholder/Analyst Call
CI
05/26Next Science Limited's Judith Mitchell to Step Down as Chief Executive Officer
CI
05/19Next Science Secures Australia, New Zealand Distributor for Wound Dressing Product
MT
05/18Next Science Limited Signed Multi-Year Distribution Agreement with Oraderm Pharmaceutic..
CI
More news
Financials (USD)
Sales 2022 16,4 M - -
Net income 2022 -7,28 M - -
Net cash 2022 10,8 M - -
P/E ratio 2022 -11,3x
Yield 2022 -
Capitalization 109 M 109 M -
EV / Sales 2022 5,97x
EV / Sales 2023 3,15x
Nbr of Employees -
Free-Float 47,2%
Chart NEXT SCIENCE LIMITED
Duration : Period :
Next Science Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEXT SCIENCE LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,51 $
Average target price 1,32 $
Spread / Average Target 161%
EPS Revisions
Managers and Directors
Judith Mitchell Chief Executive Officer, Director & MD
Jacqueline Butler Chief Financial Officer
Mark R. Compton Non-Executive Chairman
Matthew Myntti Chief Technology Officer
Jon Swanson Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NEXT SCIENCE LIMITED-36.95%112
JOHNSON & JOHNSON-3.14%435 655
ELI LILLY AND COMPANY12.76%292 179
ROCHE HOLDING AG-19.31%253 262
ABBVIE INC.4.29%249 673
PFIZER, INC.-25.35%245 989